Fresenius-licensed Endexo Smart Polymer Gets FDA Breakthrough Status to Prevent Clots
nterface Biologics Inc. (IBI) from Canada has developed Endexo as a way to help make dialyzer membranes and bloodlines more biocompatible—and less likely to clot. The technology, for which Fresenius holds an exclusive world-wide license, will reduce the need for heparin and other blood thinners.
Read the full article » | Posted 11-16-2019
Related Articles
- HD with Saline and No Blood Thinner? Posted 06-11-2025
- AWAK is now Singapore-based Vivance Posted 05-20-2025
- Archimedes by Simergent Promises Quieter, Less Painful APD Posted 05-20-2025
- PeritoneX by Relavo Medical Posted 05-20-2025